熔点 | 270°C(lit.) |
别名 | ; |
5,6-二氨基-1-甲基尿嘧啶
5,6-Diamino-1-methyluracil (订货以英文为准)
编号:D155122
CAS号:6972-82-3
分子式:C5H8N4O2
分子量:156.14
产品名称 | 5,6-Diamino-1-methyluracil |
中文名称 | 5,6-二氨基-1-甲基尿嘧啶 |
CAS号 | 6972-82-3 |
MDL编码 | D155122 |
分子式(M.F.) | C5H8N4O2 |
分子量(M.W.) | 156.14 |
储存条件 | 2-8°C储存;避光;充氩 |
Reaxys-RN | 127075 |
信号词 | Warning |
危害声明 | H315-H319-H335 |
警示性声明 | P261-P305 + P351 + P338 |
个人防护设备 | dust mask type N95 (US), Eyeshields, Gloves |
WGK德国 | 3 |
技术规格
Background: | NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. |
Applications: | WB, IHC |
Name of antibody: | RELB (Phospho-Ser573) |
Immunogen: | Synthetic peptide of human RELB (Phospho-Ser573) |
Full name: | v-rel reticuloendotheliosis viral oncogene homolog B (Phospho-Ser573) |
Synonyms: | IREL; I-REL; REL-B |
SwissProt: | Q01201 |
IHC positive control: | Human breast carcinoma |
IHC Recommend dilution: | 50-100 |
WB Predicted band size: | 70 kDa |
WB Positive control: | HUVEC cells untreated or treated with TNF |
WB Recommended dilution: | 500-1000 |
搜索质检报告(COA)
搜索MSDS
相关产品